What is a potential risk associated with beta I agonism?

The potential risk associated with beta I agonism is primarily the risk of arrhythmia. Beta I adrenergic receptors are primarily located in the cardiac tissue, and stimulation of these receptors leads to an increase in heart rate and contractility. While this response can be beneficial in certain clinical scenarios, an excessive agonistic effect on these receptors can disrupt the normal electrical conduction in the heart, leading to abnormal heart rhythms or arrhythmias. This risk is particularly significant in patients with pre-existing heart conditions or those receiving high doses of beta-agonist medications.

The other options do not align with the primary effects of beta I agonism. Increased gastrointestinal motility is more associated with parasympathetic activity. Decreased heart rate is contrary to the expected action of beta I agonism, which typically increases heart rate. Increased lung capacity does occur with beta II agonism, which is not relevant to the effects of beta I agonists. Therefore, the association of beta I agonism with the risk of arrhythmias is a critical point for healthcare providers to consider, especially in the management of patients needing cardiac support.